Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $MACK Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial evaluating ONIVYDE in patients with small-cell lung cancer into the second randomiz...
Find out more MACK - Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend
News: $MACK Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend
Dividend Amount is $1.496675 per Outstanding Share of Merrimack Common Stock and Will be Paid Today, as Previously Announced Company Provides Update on NOL Carryforwards; No Impairment as of July 24, 2019 Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or...
Got this from MACK - Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend
News: $MACK Merrimack Declares $20 Million Special Dividend
CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock. The special dividend is payable on Septem...
In case you are interested Merrimack Declares $20 Million Special Dividend
Hey. A special dividend, of over a dollar per share.....
I wonder about the timing of such a thing.....
Would that be before, or after their plans of restructuring, and a hideous reverse split, leaving me with one residual share?.....
Woo-hoo.....
LMAO.
News: $MACK Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018 . ...
Find out more https://marketwirenews.com/news-releases/merrimack-reports-fourth-quarter-and-full-year-2018-financial-results-7810514.html
Clay
Could you please interpret the chart for us?
* * $MACK Video Chart 10-19-18 * *
Link to Video - click here to watch the technical chart video
Micro-cap soon to be a nano-cap?
crazy MACK used to trade $120+
* * $MACK Video Chart 06-25-18 * *
Link to Video - click here to watch the technical chart video
What news has hit? Jumped 10% in the last hour, maybe a bit more. Can't find the reason why, at least not yet.
Been a long time since we’ve heard anything of value here. Glad to finally get some news. My bags are getting awful heavy to carry.
MACK Should be zero more dividends. They should eliminate all dividends and just keep the money. That would help increase share price.
Merrimack Pharmaceuticals (NASDAQ:MACK): Q2 EPS of -$0.22 misses by $0.08.
Can't wait for the call. Would love to see what new direction the leadership has for this beaten down biotech.
https://viralstyle.com/c/wEJJ1?
$MACK Daily and Weekly Ichimoku Chart
http://www.investopedia.com/walkthrough/forex/advanced/level7/ichimoku-cloud.aspx
This is a flipper stock until further notice
CashFreeze: you go on their website and there's been no news since 2015. What gives?
MACK drop has been on low volume. Picked up some here from my flip the other day. Dumped 75% of holdings at 1.40. Still up off the lows of mid teens. Not too worried at this point.
To approve an amendment to our certificate of incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio of one-for-ten and a proportionate reduction in the number of authorized shares of common stock, with such reverse stock split to be effected at such time and date, if at all, as determined by our board of directors in its sole discretion.
MACK WILL BE ADDED TO .... RUSSELL list AH !!!
https://www.ftserussell.com/files/support-documents/preliminary-rmicro-additions-2017
page 3/5
Lone great minds think alike!!! I got in a little early at 1.33... how did innl treat you? Also what's your target here?
Another great play for us my man!!
Gapfill 3+ weeeee
Might Even see a squeeeze here at some Point
Looking Sweet! 1,38+ today b nice
Damn...I thought I had the best grab @ $1.16. Still not complaining.
I have shares as low as 1.135. It seems to be building a step ladder slowly but noticeably
Yup...reversal confirmed.
$MACK
Lots of interest in those $1.3 shares. Guess someone's loading before that gap -fill.
Really Looking good
Hope i Got bottom
Thx Buddy
Most def looking great here! Bottom affirmed last week!!
$MACK
Yep... because the cat is still alive ... it can bounce to 1,5$ quickly
Bought yesterday and today
Could b turnaround here
* * $MACK Video Chart 06-19-17 * *
Link to Video - click here to watch the technical chart video
I see some possibility of a bounce ... one of these days
then I'm out
Lot of "T" trades at the end of the day. Settlement from the brokerage houses.
Massive volume spike at end of day last minute ....and price did not drop...
Followers
|
51
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
894
|
Created
|
03/29/12
|
Type
|
Free
|
Moderators |
Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and private management from Yale University and a BA from Stanford University.
Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008 to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA in theology from Cambridge University and a BA from Cambridge University.
Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010. Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins holds an MBA and a BS from McGill University.
Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after serving on the faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.
William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and a BA from Williams College.
Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009 to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational models of signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in Germany.
Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University and a BS from Bates College.
William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007. Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional Accounting and a BA from Williams College.
One Kendall Square
Building 700, Suite B7201
Cambridge, MA 02139
Phone: 617-441-1000
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |